TMSP(SH:600671) Xin Lang Zheng Quan·2025-11-17 06:10Core Viewpoint - Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 111.50%, but a recent decline in the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Tianmu Pharmaceutical achieved a revenue of 159 million yuan, representing a year-on-year growth of 27.48%. The net profit attributable to the parent company was 14.21 million yuan, showing a substantial increase of 484.48% compared to the previous year [2]. Stock Market Activity - As of November 17, Tianmu Pharmaceutical's stock price was 18.57 yuan per share, with a market capitalization of 2.261 billion yuan. The stock saw a trading volume of 46.34 million yuan and a turnover rate of 2.04% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on August 21, where it recorded a net buy of -55.03 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders for Tianmu Pharmaceutical was 9,693, a decrease of 6.91% from the previous period. The average circulating shares per person increased by 7.42% to 12,557 shares [2]. Business Composition - Tianmu Pharmaceutical's main business revenue composition includes health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and other (0.12%) [1]. Dividend History - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.63 million yuan in dividends, with no dividends paid in the last three years [3].